Figure 1.
Kaplan-Meier plot of progression-free survival with respect to cyclin D1 molecular response (P = 0.0001) among 118 patients with stage 4 NB treated with an immunotherapy protocol using anti-GD2 antibody 3F8 plus GM-CSF. Marrow response was defined in the Materials and Methods section. Follow-up marrows were evaluated at 2.5 months from protocol entry.